Evidence map›Paper›PMID 27481898›Full record

ArticleThe Journal of rheumatology2016

Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?

Adam J N Raymakers, Nicole W Tsao, Carlo A Marra, Philip J Clements, Dinesh Khanna

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Adam J N RaymakersFrom the Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia; School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; University of Michigan, Ann Arbor, Michigan; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA.A.J. Raymakers, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; N.W. Tsao, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; C.A. Marra, PhD, School of Pharmacy, Memorial University of Newfoundland; P.J. Clements, MD, Division of Rheumatology, David Geffen School of Medicine, UCLA; D. Khanna, MD, MSc, University of Michigan.
Nicole W TsaoFrom the Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia; School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; University of Michigan, Ann Arbor, Michigan; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA.A.J. Raymakers, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; N.W. Tsao, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; C.A. Marra, PhD, School of Pharmacy, Memorial University of Newfoundland; P.J. Clements, MD, Division of Rheumatology, David Geffen School of Medicine, UCLA; D. Khanna, MD, MSc, University of Michigan.
Carlo A MarraFrom the Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia; School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; University of Michigan, Ann Arbor, Michigan; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA.A.J. Raymakers, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; N.W. Tsao, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; C.A. Marra, PhD, School of Pharmacy, Memorial University of Newfoundland; P.J. Clements, MD, Division of Rheumatology, David Geffen School of Medicine, UCLA; D. Khanna, MD, MSc, University of Michigan.
Philip J ClementsFrom the Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia; School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; University of Michigan, Ann Arbor, Michigan; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA.A.J. Raymakers, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; N.W. Tsao, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; C.A. Marra, PhD, School of Pharmacy, Memorial University of Newfoundland; P.J. Clements, MD, Division of Rheumatology, David Geffen School of Medicine, UCLA; D. Khanna, MD, MSc, University of Michigan.
Dinesh KhannaFrom the Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia; School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada; University of Michigan, Ann Arbor, Michigan; Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, California, USA.A.J. Raymakers, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; N.W. Tsao, MSc, CORE, Faculty of Pharmaceutical Sciences, University of British Columbia; C.A. Marra, PhD, School of Pharmacy, Memorial University of Newfoundland; P.J. Clements, MD, Division of Rheumatology, David Geffen School of Medicine, UCLA; D. Khanna, MD, MSc, University of Michigan. khannad@med.umich.edu.
Memorial University of Newfoundland · CA

Funding

Outcomes Research in Rheumatic DiseasesK24AR063120 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KHANNA, DINESH · 2012 to 2022
$1.6M
NIAMS NIH HHS K24 AR063120
6 · The paper itself

Abstract

objectiveHealth state utility values (HSUV) are used as weightings to calculate quality-adjusted life years in economic evaluations. Evidence suggests that patients' perceptions of a new diagnosis for a chronic disease, while initially poor, may improve over time. The objective of this study was to examine the association between disease duration and direct HSUV scores in patients with systemic sclerosis (SSc).

methodsOur study included patients with SSc from a US SSc center. An interviewer administered direct HSUV techniques including the visual analog scale (VAS), time tradeoff (TTO), and standard gamble (SG). We calculated the Short Form 6D HSUV from the Medical Outcomes Study Short Form-36. Additional clinical and demographic variables were collected.

resultsThe mean age of the SSc sample (n = 223) was 51 years (SD 16) with the majority being women (84%). Median disease duration was 5 years (interquartile range 1.5-9). Mean (SD) HSUV scores were 0.67 (0.19) for the VAS, 0.76 (0.28) for the TTO, 0.84 (0.22) for the SG, and 0.65 (0.13) for the SF-6D. In patients with early disease (defined as ≤ 2 yrs, n = 78), the mean HSUV values were 0.64 (VAS), 0.70 (TTO), 0.80 (SG), and 0.63 (SF-6D) versus for those with a longer disease duration: 0.69, 0.79, 0.87, and 0.67, respectively. In multivariate analysis, the SG measure showed a significant and positive association with disease duration measured as a continuous variable and using a threshold of 2 years (p = 0.047 and p = 0.023, respectively).

conclusionGreater disease duration showed a positive association with a direct measure (SG) of utility elicitation after a period of 2 years.

Indexed as

Quality of LifeAdultAgedFemaleHealth StatusHumansMaleMiddle AgedPain MeasurementPatient SatisfactionQuality-Adjusted Life YearsScleroderma, SystemicSeverity of Illness IndexSymptom AssessmentVisual Analog ScaleDISEASE DURATIONHEALTH STATE UTILITY VALUESQUALITY OF LIFESTANDARD GAMBLESYSTEMIC SCLEROSISUTILITY SCORE

Identifiers

PMID27481898
PMCPMC5050095
OpenAlexW2498817900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.